NCT02036476View on ClinicalTrials.gov

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

July 31, 2016

Conditions
Merkel Cell CarcinomaSkin Cancer
Interventions
DRUG

Cabozantinib

oral administration

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER